June 18, 2026Journal of the American College of Cardiology47 citations
View Full PaperTricuspid Regurgitation in Patients With Heart Failure and Preserved Ejection Fraction
Key Result
This review discusses the coexistence of heart failure with preserved ejection fraction and tricuspid regurgitation, suggesting possible management strategies including transcatheter treatments.
Key Points
- This review aims to explore the relationship between tricuspid regurgitation and heart failure with preserved ejection fraction, suggesting management strategies.
- Review of current literature on heart failure with preserved ejection fraction and tricuspid regurgitation.
- Discussion on the implications of transcatheter treatment and its effects on patient outcomes.
- Analysis of the coexistence of heart failure and tricuspid regurgitation.
- Identified risk factors for heart failure with preserved ejection fraction and tricuspid regurgitation are similar.
- Management of heart failure may positively affect symptoms of tricuspid regurgitation.
- Transcatheter device trials possibly target advanced heart failure with preserved ejection fraction patients.
Structured PICO
P
Population
Patients with Heart Failure and Preserved Ejection Fraction (HFpEF) and Tricuspid Regurgitation (TR)
I
Intervention
Management strategies including transcatheter treatment of TR
This review highlights the frequent coexistence of HFpEF and tricuspid regurgitation, suggesting that management of one condition may impact the pathophysiology and outcomes of the other.
Abstract
Heart failure with preserved ejection fraction (HFpEF) is associated with high morbidity and mortality. Important risk factors for the development of HFpEF are similar to risk factors for the progression of tricuspid regurgitation (TR), and both conditions frequently coexist and thus is a distinct phenotype or a marker for advanced HF. Many patients with severe, symptomatic atrial secondary TR have been enrolled in current transcatheter device trials, and may represent patients at an advanced stage of HFpEF. Management of HFpEF thus may affect the pathophysiology of TR, and the physiologic changes that occur following transcatheter treatment of TR, may also impact symptoms and outcomes in patients with HFpEF. This review discusses these issues and suggests possible management strategies for these patients.